[go: up one dir, main page]

WO2013039374A3 - Method for extracting, testing and counting dialysed leukocyte extract from shark spleen in order to obtain an enhanced transfer factor, specifically designed to be used as a treatment against the disease known as vitiligo - Google Patents

Method for extracting, testing and counting dialysed leukocyte extract from shark spleen in order to obtain an enhanced transfer factor, specifically designed to be used as a treatment against the disease known as vitiligo Download PDF

Info

Publication number
WO2013039374A3
WO2013039374A3 PCT/MX2012/000085 MX2012000085W WO2013039374A3 WO 2013039374 A3 WO2013039374 A3 WO 2013039374A3 MX 2012000085 W MX2012000085 W MX 2012000085W WO 2013039374 A3 WO2013039374 A3 WO 2013039374A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitiligo
dialysed
counting
extracting
testing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2012/000085
Other languages
Spanish (es)
French (fr)
Other versions
WO2013039374A2 (en
Inventor
Héctor Manuel ZEPEDA LÓPEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013039374A2 publication Critical patent/WO2013039374A2/en
Publication of WO2013039374A3 publication Critical patent/WO2013039374A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a leukocyte extract which contains polypeptides up to 10,000 daltons from shark spleen and to the use thereof as a drug for treating the disease known as vitiligo. Said extract is a dialyzable leukocyte extract, specifically from the spleen, which is part of the lymphatic system and is the main organ in the immune system of the Selachimorpha, a superorder of the Chondrichthyes, commonly known as sharks, for obtaining enhanced transfer factor.
PCT/MX2012/000085 2011-09-15 2012-09-13 Method for extracting, testing and counting dialysed leukocyte extract from shark spleen in order to obtain an enhanced transfer factor, specifically designed to be used as a treatment against the disease known as vitiligo Ceased WO2013039374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535089P 2011-09-15 2011-09-15
US61/535,089 2011-09-15

Publications (2)

Publication Number Publication Date
WO2013039374A2 WO2013039374A2 (en) 2013-03-21
WO2013039374A3 true WO2013039374A3 (en) 2013-05-02

Family

ID=47883903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2012/000085 Ceased WO2013039374A2 (en) 2011-09-15 2012-09-13 Method for extracting, testing and counting dialysed leukocyte extract from shark spleen in order to obtain an enhanced transfer factor, specifically designed to be used as a treatment against the disease known as vitiligo

Country Status (1)

Country Link
WO (1) WO2013039374A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318384A1 (en) * 2015-06-04 2018-11-08 Hector Manuel Zepeda Lopez Strengthened t-cell modulator that can modulate the immune response, specifically designed for therapeutic use for the treatment of the disease known as vitiligo

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081076A1 (en) * 2006-09-29 2008-04-03 Lisonbee David A Nanofraction immune modulators, preparations and compositions including the same, and associated methods
US20080206171A1 (en) * 2007-02-26 2008-08-28 L'oreal Conditioned medium and uses thereof
MX2008009296A (en) * 2008-07-18 2010-01-18 Carlos Adolfon Perez De La Mora Optimised process for the obtention of dialyzable leukocyte extract, containing peptides with molecular weight equal to or lower than 10,000 daltons, from crocodile lymphoid tissue and the preparation thereof in an oral and/or injectable pharmaceutic
ES2353208T3 (en) * 2002-02-28 2011-02-28 Luis Antonio Calzada Nova DIALIZED LEUCOCITE EXTRACT FOR THE TREATMENT OF INFECTIOUS DISEASES IN ANIMALS.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353208T3 (en) * 2002-02-28 2011-02-28 Luis Antonio Calzada Nova DIALIZED LEUCOCITE EXTRACT FOR THE TREATMENT OF INFECTIOUS DISEASES IN ANIMALS.
US20080081076A1 (en) * 2006-09-29 2008-04-03 Lisonbee David A Nanofraction immune modulators, preparations and compositions including the same, and associated methods
US20080206171A1 (en) * 2007-02-26 2008-08-28 L'oreal Conditioned medium and uses thereof
MX2008009296A (en) * 2008-07-18 2010-01-18 Carlos Adolfon Perez De La Mora Optimised process for the obtention of dialyzable leukocyte extract, containing peptides with molecular weight equal to or lower than 10,000 daltons, from crocodile lymphoid tissue and the preparation thereof in an oral and/or injectable pharmaceutic

Also Published As

Publication number Publication date
WO2013039374A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
CY2017019I1 (en) FACTORS AFFECTING APOSTIPLOSIS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
WO2012038068A3 (en) Means and methods for the prediction of treatment response of a cancer patient
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500867A1 (en) Dual variable domain immunoglobulins and uses thereof
EP2658561A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same
WO2014144280A8 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
WO2013058640A3 (en) Method for the extraction, verification and counting of dialyzed leukocyte extract originating from shark spleen in order to obtain potentialized transfer factor, specifically designed for use as treatment against the disease known as asthma
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
PT2945642T (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
SI2900279T1 (en) GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
HK1214764A1 (en) Method and composition for inducing autophagy
WO2015187727A3 (en) Molecular mammography
EP3024482A4 (en) Methods for diagnosing and treating immune disease
MX2018000528A (en) Device for detecting misfolded proteins and methods of use therof.
WO2014133728A3 (en) Hhla2 as a novel inhibitor of human immune system and uses thereof
WO2011050351A3 (en) Methods and kits used in identifying glioblastoma
WO2013043032A3 (en) Dialysed extract of leucocytes from shark spleen, for obtaining a transfer factor with increased potential, specifically designed to be used as an immunomodulator, and method for extracting, checking and counting same
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2014169011A3 (en) Methods for treating immune diseases
MX2015005111A (en) Herbal composition for the prevention and treatment of tnf-î± mediated diseases.
WO2013039374A3 (en) Method for extracting, testing and counting dialysed leukocyte extract from shark spleen in order to obtain an enhanced transfer factor, specifically designed to be used as a treatment against the disease known as vitiligo
PH12015500223B1 (en) Method for manufacturing low-protein rice and food using low-protein rice

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12831506

Country of ref document: EP

Kind code of ref document: A2